BI 3034701 is an investigational peptide that combines activity at three receptors: GLP-1, GIP and NPY2. It is now being tested in a recruiting Phase 2 study for adults with obesity or overweight.
That status is easy to overstate. The trial’s existence shows that the program has advanced beyond initial human testing; it does not show how much weight the candidate produces, whether the NPY2 component adds a clinical benefit or whether the eventual benefit-risk profile will support approval. No Phase 2 results were posted as of August 12, 2026.
BI 3034701 at a glance
| Attribute | Current public information |
|---|---|
| Developer | Boehringer Ingelheim |
| Discovery origin | Gubra; developed through the companies’ obesity collaboration |
| Receptor targets | GLP-1 + GIP + NPY2 |
| Current stage | Phase 2, recruiting |
| Registered study | NCT07662122 |
| Estimated enrollment | 300 participants |
| Treatment period | 42 weeks |
| Primary endpoint | Percentage change in body weight from baseline at week 42 |
| Posted Phase 2 results | None as of August 12, 2026 |
| FDA approved | No |
The registry was updated on August 6, 2026, and lists a seven-group, randomized, placebo-controlled dose-finding design: six BI 3034701 dose groups and one placebo group. The entry also states that participants with type 2 diabetes are excluded. Those details matter when future results are compared with trials conducted in different populations.
What makes this a triple agonist?
“Triple agonist” means that one molecule is designed to activate three receptor systems. It does not describe a fixed class effect, because the third target and the balance of activity can differ markedly between candidates.
The GLP-1 component places BI 3034701 within a well-established area of metabolic drug development. GIP adds a second incretin pathway, familiar from the dual agonist tirzepatide. NPY2, also called the Y2 receptor, is the distinctive third part of this program and is involved in neural signaling related to appetite and food intake.
Boehringer Ingelheim’s hypothesis is that NPY2 activity may complement the GIP and GLP-1 components. That remains a hypothesis until the dose-response, tolerability and efficacy data are available. A receptor diagram cannot predict the contribution of each pathway in people.
Gubra’s discovery-program page describes BI 3034701 as a potential first-in-class GLP-1/GIP/NPY2 triple agonist and reports that Phase 1 was completed before Phase 2 began. Boehringer Ingelheim stated in its July 2026 development announcement that Phase 1 safety and tolerability were generally favorable. No numerical Phase 1 efficacy dataset or peer-reviewed Phase 2 result was included in that announcement.
BI 3034701 versus retatrutide and survodutide
These candidates are often placed in the same headline, but they do not test the same receptor combination.
| Candidate | Receptor design | Development context in August 2026 |
|---|---|---|
| BI 3034701 | GLP-1 + GIP + NPY2 | Recruiting Phase 2 dose-finding study |
| Retatrutide | GIP + GLP-1 + glucagon | Phase 3 obesity program |
| Survodutide | GLP-1 + glucagon | Phase 3 obesity and MASH programs |
| Tirzepatide | GIP + GLP-1 | Active ingredient in FDA-approved products |
The clearest comparison is with retatrutide. Both are triple-receptor agonists, but retatrutide uses glucagon as its third target, whereas BI 3034701 uses NPY2. This changes the biological question being tested. It does not establish that either design is stronger.
Relative potency, exposure, titration and tolerability can matter as much as the names of the receptors. Without a direct randomized trial, cross-study results cannot reliably show that one candidate is superior. For the evidence available on the later-stage molecule, read our retatrutide Phase 3 results guide.
What the Phase 2 trial is designed to answer
The 42-week Phase 2 study is primarily a dose-finding trial. ClinicalTrials.gov lists six active-treatment groups, which should help investigators examine whether increasing exposure produces a consistent effect and where adverse effects or treatment discontinuation begin to limit usable dosing.
The primary endpoint is percentage change in body weight from baseline at week 42. Secondary endpoints include the proportions of participants reaching at least 5%, 10%, 15% and 20% weight loss, along with changes in absolute body weight, waist circumference and blood pressure.
When results arrive, the largest percentage will not be enough to judge the program. The interpretation should include how many participants reached their assigned dose, how missing data were handled, the discontinuation rate and the frequency and severity of adverse events. The dose-response pattern will be especially important because a multi-receptor design may not behave as a simple sum of three pathways.
The registry estimates primary completion in August 2027. That date can change, and a completion date is not the same as a public-results date. Until results are posted or presented, claims about the candidate’s weight-loss percentage are speculation.
What is actually known today
The evidence can be separated into three levels. The receptor design and trial protocol are public facts. The sponsor has reported generally favorable Phase 1 safety and tolerability. Phase 2 efficacy and longer-term safety remain unknown.
That last category is the largest one. There is no basis yet for claiming that BI 3034701 outperforms tirzepatide, retatrutide or any approved medicine. It is also not available as an approved treatment. Products marketed online under the name of an investigational candidate should not be confused with authorized clinical-trial access.
Research-use boundary
Certiva supplies peptide reference materials for controlled laboratory research only. A research material is not a medicine and is not a substitute for an authorized clinical trial or approved prescription product.
Researchers assessing an unfamiliar peptide should verify identity, purity and batch traceability separately. Our guides to reading a peptide COA and peptide batch traceability explain the documentation questions to ask before accepting a research lot.
Sources and further reading
- ClinicalTrials.gov: Phase 2 study NCT07662122
- Gubra: discovery programs and BI 3034701 status
- Boehringer Ingelheim: BI 3034701 enters Phase 2, July 16, 2026
- ClinicalTrials.gov: completed Phase 1 study NCT06352437
This article reports public research and development information as of August 12, 2026. It is not medical advice and does not recommend use of an investigational product.
Frequently asked questions
What is BI 3034701?
BI 3034701 is an investigational peptide designed to activate GLP-1, GIP and NPY2 receptors. Boehringer Ingelheim is studying it as a potential treatment for obesity and overweight.
What phase is BI 3034701 in?
BI 3034701 is in Phase 2. ClinicalTrials.gov listed study NCT07662122 as recruiting in August 2026, with an estimated enrollment of 300 participants and a 42-week treatment period.
Is BI 3034701 FDA approved?
No. BI 3034701 is investigational and is not FDA approved. A recruiting Phase 2 trial does not establish efficacy or an acceptable benefit-risk profile.
How is BI 3034701 different from retatrutide?
Their third receptor targets differ. BI 3034701 targets GLP-1, GIP and NPY2 receptors, while retatrutide targets GIP, GLP-1 and glucagon receptors. No head-to-head comparison has been reported.
Are Phase 2 weight-loss results available for BI 3034701?
No. As of August 12, 2026, the Phase 2 registry had no posted results. Its primary endpoint is percentage change in body weight from baseline at week 42.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →